James J Harding, Associate Member of Gastrointestinal Oncology and Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post by Jason Lewis, Emily Tow Chair, Deputy Director at Memorial Sloan Kettering Cancer Center, adding:
“Important target for GEP NECs! And another great collaboration with STGI and Molecular Medicine.”
Quoting Jason Lewis‘s post:
“Out today in JCO Precision Oncology “Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms“. We show that DLL3 is expressed on a majority of GEP NECs and on a subset of high-grade PanNETs marked by poor outcomes. Functional imaging suggests DLL3 as a promising therapeutic target in both GEP NECs and high-grade PanNETs.”
Title: Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Authors: Rohit Thummalapalli, Salomon Tendler, Joanne Chou, Zeynep Tarcan, Courtney Porfido, Jonathan Willner, Irina Linkov, Umesh Bhanot, Alissa Cooper, Jierui Xu, James Harding, Natasha Rekhtman, Laura Tang, Charles Rudin, Yelena Janjigian, Heiko Schöder, John Porier, Jinru Shia, Olca Basturk, Diane Reidy-Lagunes, Marinela Capanu, Jason Lewis, Lisa Bodei, Mark Dunphy, Nitya Raj
Read the Full Article.
